Welcome to Advance Tests, where innovation meets accessibility in diagnostic solutions.
Through an exclusive collaboration with Lucent Diagnostics, we’re proud to offer LucentAD Complete to healthcare providers across the UK. This advanced, multi-marker blood test is specifically designed to aid in Alzheimer’s disease diagnostics, bringing a new level of accuracy and patient accessibility to the field.
Extensive Validation
LucentAD Complete offers an unparalleled solution for assessing risk of amyloid pathology in patients with mild cognitive impairment (MCI) or early cognitive symptoms. This blood test is backed by clinical validation and is a preferred alternative to more invasive and costly diagnostic methods, such as cerebrospinal fluid (CSF) testing and PET imaging.
MEDICAL PROFESSIONAL?
LucentAD Complete: A New Standard in Alzheimer’s Diagnostics for Medical Professionals
KEY ADVANTAGES
01
Cost Effective
At £695, LucentAD Complete is an affordable option that makes amyloid pathology risk assessment more accessible to a larger number of patients who are experiencing symptoms.
02
Non-Invasive
The test requires only a blood sample, significantly reducing patient discomfort and procedural risks associated with gold standard CSF or PET.
03
High Sensitivity and Specificity
Utilizing a multi-marker approach, LucentAD Complete achieves diagnostic accuracy that meets or exceeds the thresholds recommended by leading Alzheimer’s research bodies, including the Global CEO Initiative on Alzheimer’s Disease (CEOi).
04
Streamlined Testing & Results
The test offers a quick 15 working day turnaround, with results presented as a clear amyloid risk score that is accessible through a secure portal.
Multi-Marker Strategy
LucentAD Complete is an algorithmic, multi-analyte test designed to accurately classify amyloid status by quantifying multiple biomarkers. This approach combines p-Tau 217 (a highly accurate marker of Alzheimer’s amyloid pathology) with additional plasma biomarkers, including Nfl, Aβ42/40 ratio, and GFAP*. Together, these biomarkers improve the diagnostic clarity, especially in cases that might otherwise yield inconclusive results with p-Tau 217 alone.
pTau-217
This biomarker provides the primary basis for amyloid classification due to its high correlation with amyloid PET imaging. Phosphorylated tau at the 217 position is recognized as a leading plasma biomarker for Alzheimer’s disease detection.
To learn more about LucentAD Complete and how it can support your practice, please complete the contact us form.
Our experienced team is available to answer questions, provide resources, and guide you through the integration of this advanced diagnostic tool into your patient care protocols.
NfL
(Neurofilament Light Chain). Provides additional information on neurodegeneration, enabling further discrimination in cases of cognitive impairment.
Aβ42/40 Ratio
Directly reflecting amyloid plaque pathology, this ratio is used to further enhance accuracy.
GFAP
(Glial Fibrillary Acidic Protein). Reflects astrocytic activation associated with Alzheimer’s pathology.
These biomarkers are processed through Lucent Diagnostic’s Simoa technology for ultra-sensitive detection, achieving levels of precision necessary for clinical use. Through a logistic regression model, the test assigns an amyloid risk score between 0 and 100, categorizing results into low, intermediate, or high risk.
*GFAP is offered pursuant to a license from Banyan Biomarkers Inc. Banyan GFAP is a registered trademark of Banyan Biomarkers.
Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.
Clinical Validation & Performance
LucentAD Complete has undergone validation across multiple independent cohorts, ensuring robust performance across diverse patient populations. Studies indicate:
-
90% Diagnostic Accuracy: High levels of sensitivity and specificity in amyloid classification, aligning with standards set by the Global Initiative.
-
Reduced Intermediate Zone: The inclusion of multi-marker analysis reduces the "intermediate" diagnostic range by approximately three-fold, providing more conclusive results for a larger proportion of patients.
Medical Professional?
Patients with Cognitive Impairment
Ideal for patients with MCI or early cognitive symptoms, for whom early diagnosis may enable timely therapeutic intervention.
Individuals with High Alzheimer's Risk
Individuals with High Alzheimer’s Risk: Includes patients with a family history or genetic predisposition to Alzheimer’s disease who are displaying symptoms.
Avoidance of Invasive Procedures
Especially beneficial for patients with contraindications to lumbar puncture or those unable to access PET imaging.
Direct Referral
Medical professionals can refer patients directly for the LucentAD Complete test through our secure portal. We will invoice you after the test.
Patient Self-Booking
Patients can also schedule their own appointments, with the option for your office to receive test results securely for review.
London Clinic
Our primary testing facility is conveniently located on St Thomas Street in London, directly adjacent to Guy’s Hospital, with additional UK locations planned. Tell us here where you'd like us to open the next clinic.